Kopran Limited

Equities

KOPRAN

INE082A01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-04-25 am EDT 5-day change 1st Jan Change
260 INR -0.95% Intraday chart for Kopran Limited -2.44% +7.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Kopran Limited Announces Renewal of Gmp Compliance Certificate by Medicines & Healthcare Products Regulatory Agency of United Kingdom (Mhra - Uk) CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Revises Outlook to Negative MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Kopran Limited Recommends Dividend for the Year Ended March 31, 2023 CI
Kopran Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Crisil Keeps BBB+ Rating on Kopran's Bank Loans; Outlook Stable MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Kopran Arm Acquires Active Pharmaceutical Ingredient Manufacturing Unit Assets in India MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Kopran Limited Recommends Dividend for the Financial Year 2021-2022 CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Kopran Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Outlook Stable MT
Kopran Invests Over $13 Million in Subsidiary MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Kopran Limited announced that it has received INR 1.264799745 billion in funding from Mahima STOCKS Private Limited, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited CI
Pharmaceuticals Manufacturer Kopran's Arm Gets New Patent in India MT
Kopran Limited announced that it expects to receive INR 1.264799745 billion in funding from Mahima Stocks Pvt Ltd, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited and other investors CI
Kopran's Board to Consider Issuance of Equity Shares MT
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Kopran : Arm Resumes Production at Flood-Hit Unit MT
Chart Kopran Limited
More charts
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
More about the company
  1. Stock Market
  2. Equities
  3. KOPRAN Stock
  4. News Kopran Limited
  5. Kopran Arm Acquires Active Pharmaceutical Ingredient Manufacturing Unit Assets in India